NuVasive develops what it calls “minimally disruptive” surgical products and procedures for the spine, including applications for spine fusion surgery, including biologics. The company expanded in 2013, opening shop in Japan and buying its contract manufacturer, ANC LLC. Its product offering includes a surgical platform, Maximum Access Surgery, and an array of biologics, cervical and motion preservation products. The company’s spine surgery products include offerings for the thoracolumbar spine. NuVasive is also developing a set of motion-preservation products. Its biologics line includes allografts from donated human tissue; FormaGraft, a collagen synthetic product used to aid the fusion process; and Osteocel Plus, an allograft cellular matrix containing viable mesenchymal stem cells.